- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00933465
Imodium Syrup Versus Imodium Tablets for Faecal Incontinence
Single Blinded Randomised Cross-over Study of Imodium Tablets Versus Imodium Syrup for the Treatment of Faecal Incontinence
Faecal incontinence (FI) is a debilitating and often neglected problem. It can be defined as the loss of voluntary control of liquid or solid stool.It is estimated that 2-3% of western adults suffer from FI with prevalence increasing with age, further to this up to 50% of nursing home residents suffer too with it more common in females. Aetiology is often multi-factoral, where obstetric anal sphincter injury is most common is females and iatrogenic anal sphincter injury is most common in males.
Loperamide (imodium) is a constipating agent used as first choice pharmacological agent due to its high efficacy. Trials have suggested it thickens stool consistency and may raise resting anal sphincter pressure, associated with improved clinical function with a reduction in bowel frequency and urgency, a reduction in incontinence and less need for pads.
Loperamide is well tolerated but has been known to cause side effects of abdominal pain and distension, nausea and vomiting and constipation.
Imodium can be taken in two ways; as syrup (1mg/5mls) or tablets (2mg). There have been no comparative studies. Side effects are mainly seen with the tablet form and so it is hypothesized that the syrup form is better tolerated because it is more accurately titrated to effect.
This is a NHS funded single blinded, randomised, cross-over study to assess the clinical effects of Imodium, in tablet and syrup form, on patients presenting with faecal incontinence. Each subject will act as their own control. Patients will be recruited through out-patient visits for their FI, where they will be made aware of the trial. During the trial they will be asked to fill out FI scoring questionnaires and quality of life scores. Also they will undertake two assessments of anal physiology testing squeeze pressures, sensation and compliance at baseline and at the end after three months.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Hampshire
-
Southampton, Hampshire, United Kingdom, SO16 6YD
- Southampton General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 - 75
- Severe faecal incontinence defined as greater than one episode per week of involuntary loss of either solid or liquid stool as demonstrated by means of a baseline bowel habit and a Vaizey score of greater than 4.
- Competent and willing to fill in questionnaires and attend follow up clinics through out the study period.
Exclusion Criteria:
- Alternating bowel habit, associated with symptoms of constipation. Use of other regular or as required medications that may affect bowel function. (e.g. codeine phosphate).
- Patients with complete or partial spinal cord injuries including cauda equina syndrome.
- Active inflammatory bowel disease.
- Pregnancy
- Stoma in situ
- Psychiatric and physiological inability to comply with study protocol.
- Non english speakers (student project funding cannot cover interpreter and other costs)
(application of criteria at the discretion of the investigating doctor at initial consultation)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: tablets first followed by syrup
first 6 weeks of study using tablets, then followed by assessment, and then the next 6 weeks using syrup, followed by assessment
|
syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms. Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most. tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms. Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most |
Experimental: Syrup first followed by tablets
first 6 weeks of study using syrup, then followed by assessment, and then the next 6 weeks using tablets, followed by assessment
|
syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms. Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most. tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms. Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the use of imodium as tablets or syrup in the treatment of faecal incontinence in order to improve the scores of patients with faecal incontinence as seen with continence and quality of life questionnaires
Time Frame: 2 sets of 6 weeks (3 months)
|
2 sets of 6 weeks (3 months)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To reduce to number of patients suffering from faecal incontinence
Time Frame: 3 months
|
3 months
|
Number of episodes of total, urge and passive incontinence
Time Frame: 3 months
|
3 months
|
Total number of patient incontinent days
Time Frame: 3 months
|
3 months
|
Use of pads and other medications
Time Frame: 3 months
|
3 months
|
Ability to defer defaecation
Time Frame: 3 months
|
3 months
|
Adverse effects relating to medication
Time Frame: 3 months
|
3 months
|
Determining the direct medical costs, direct non-medical costs, indirect non-medical costs associated with the treatment of Faecal incontinence, and cost effectiveness of treatment with syrup and tablets
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Karen Nugent, MA MSmedFRCS, University Hospital Southampton NHS Foundation Trust
Publications and helpful links
General Publications
- Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology. 1980 Dec;79(6):1272-5.
- Cheetham M, Brazzelli M, Norton C, Glazener CM. Drug treatment for faecal incontinence in adults. Cochrane Database Syst Rev. 2003;(3):CD002116. doi: 10.1002/14651858.CD002116.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RHMMED0874
- eudraCT number; 2009-013776-49
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fecal Incontinence
-
Batterjee Medical CollegeBenha UniversityCompleted
-
Badr UniversityCompletedFecal Incontinence in ChildrenEgypt
-
Hospital Mutua de TerrassaCompletedGas Incontinence | Soilings, Fecal
-
RDD Pharma LtdWithdrawnIdiopathic Fecal IncontinenceIsrael
-
Nantes University HospitalCompletedConstipation Aggravated | Fecal Incontinence With Fecal UrgencyFrance
-
Queen Mary University of LondonCompletedBowel Incontinence | Faecal Incontinence
-
University of AarhusUniversity of Tromso; Hvidovre University HospitalCompletedFecal Incontinence | Faecal IncontinenceDenmark
-
NICHD Pelvic Floor Disorders NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFecal Incontinence | Bowel IncontinenceUnited States
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompleted
-
Massarat ZutshiCook Group IncorporatedTerminatedFecal Incontinence | Anal IncontinenceUnited States
Clinical Trials on Imodium (Loperamide Hydrochloride) syrup
-
Johnson & Johnson Consumer and Personal Products...Completed
-
Odense University HospitalTerminatedRectal Cancer | Ulcerative Colitis | Short Bowel SyndromeDenmark
-
McNeil ABCompleted
-
The University of Texas Health Science Center,...Completed
-
Xian-Janssen Pharmaceutical Ltd.Completed
-
Johnson & Johnson Consumer and Personal Products...Completed
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital with Nanjing Medical University; Zhejiang Cancer... and other collaboratorsWithdrawnChemotherapy-related DiarrheaChina
-
NICHD Pelvic Floor Disorders NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFecal IncontinenceUnited States
-
McNeil ABCompleted
-
Boehringer IngelheimCompleted